Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

SPI-62, now clofutriben, normalizes cortisol levels in Phase 2 trial

Sparrow Pharmaceuticals’ oral small molecule SPI-62, now being called clofutriben, can lower the levels of free cortisol in the urine of people with Cushing’s syndrome caused by a tumor outside the adrenal glands, including those with Cushing’s disease. Unlike other cortisol-lowering medications, which require careful dosing to prevent…

Glucocorticoid therapy may safely await day after surgery: Study

For people who undergo surgery to treat Cushing’s disease or other forms of endogenous Cushing’s syndrome, replacement treatment with glucocorticoids may not be necessary immediately before or after the procedure, a study suggests. Rather, findings favored “withholding perioperative glucocorticoids until the first postoperative day (or even longer),” the researchers…

Top 10 Cushing’s disease stories of 2023

In 2023, Cushing’s Disease News brought readers comprehensive coverage of the latest scientific research and developments in treatment for Cushing’s disease. Here are the 10 most-read news stories of 2023, along with a brief description of each. We look forward to continuing to serve as a resource for…

Locating tumors by IPSS may not lead to better surgery outcomes

Accurately locating tumors in the brain’s pituitary gland by inferior petrosal sinus sampling or IPSS — an invasive test that’s been considered the gold standard for diagnosing Cushing’s disease — may not necessarily lead to better outcomes after surgery, according to a new meta-analysis. While IPSS correctly determined…